Peter Shalit

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study

Grace A. McComsey, Douglas Ward, Siegrid M. Hessenthaler et al. · Clinical Infectious Diseases · 2004 · 187 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care

Elyse Tung, Annalisa Thomas, Allyson Eichner et al. · Sexual Health · 2018 · 150 citations

Pharmacy, Community Pharmacy, Pharmacy Practice +15

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

Anthony Mills, Gordon Crofoot, Cheryl McDonald et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 140 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17